Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Current Assets (2016 - 2025)

vTv Therapeutics (VTVT) has disclosed Current Assets for 12 consecutive years, with $89.9 million as the latest value for Q4 2025.

  • Quarterly Current Assets rose 135.86% to $89.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $89.9 million through Dec 2025, up 135.86% year-over-year, with the annual reading at $89.9 million for FY2025, 135.86% up from the prior year.
  • Current Assets hit $89.9 million in Q4 2025 for vTv Therapeutics, down from $99.5 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $99.5 million in Q3 2025 to a low of $9.2 million in Q1 2021.
  • Historically, Current Assets has averaged $32.1 million across 5 years, with a median of $26.7 million in 2022.
  • Biggest five-year swings in Current Assets: skyrocketed 502.8% in 2021 and later tumbled 64.82% in 2023.
  • Year by year, Current Assets stood at $15.6 million in 2021, then surged by 73.45% to $27.1 million in 2022, then crashed by 60.67% to $10.7 million in 2023, then surged by 257.63% to $38.1 million in 2024, then soared by 135.86% to $89.9 million in 2025.
  • Business Quant data shows Current Assets for VTVT at $89.9 million in Q4 2025, $99.5 million in Q3 2025, and $26.4 million in Q2 2025.